Cocrystal Pharma, Inc. (COCP)

NASDAQ: COCP · IEX Real-Time Price · USD
0.530
-0.023 (-4.11%)
At close: Jan 21, 2022 4:00 PM
0.511
-0.019 (-3.566%)
After-hours:Jan 21, 2022 7:37 PM EST
Market Cap51.66M
Revenue (ttm)510,000
Net Income (ttm)-11.99M
Shares Out97.47M
EPS (ttm)-0.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume551,490
Open0.550
Previous Close0.553
Day's Range0.501 - 0.565
52-Week Range0.500 - 3.460
Beta0.62
AnalystsBuy
Price Target4.50 (+749.1%)
Earnings Daten/a

About COCP

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for...

IndustryPharmaceuticals
CEOGary Wilcox
Employees13
Stock ExchangeNASDAQ
Ticker SymbolCOCP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for COCP stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 749.06% from the latest price.

Price Target
$4.50
(749.06% upside)
Analyst Consensus: Buy

News

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022

2 weeks ago - GlobeNewsWire

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies.  The Company earlier confirmed that its protease inhibitors d...

1 month ago - Benzinga

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Again...

Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma

1 month ago - GlobeNewsWire

4 Biotech Penny Stocks to Watch With New Catalysts

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:CTICETONOBSV
1 month ago - PennyStocks

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Mark...

BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO Jam...

1 month ago - GlobeNewsWire

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at ...

Unveils designs for Phase 1 and 2 stud ies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors ; trial initiations expected in 2022

1 month ago - GlobeNewsWire

Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know

Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviru...

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-...

2 months ago - GlobeNewsWire

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expe...

2 months ago - Benzinga

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance o...

FDA 's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205

2 months ago - GlobeNewsWire

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

3 months ago - GlobeNewsWire

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of ...

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...

3 months ago - GlobeNewsWire

5 Best Penny Stocks To Buy Right Now According To Insiders

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ALTOEYENHOFVSCPS
4 months ago - PennyStocks

Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know

Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Var...

Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma...

5 months ago - Benzinga

8 Hot Penny Stocks That You Should Add to Your July Watchlist

With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, ...

6 months ago - PennyStocks

Cocrystal Joins Russell Microcap® Index

BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...

6 months ago - GlobeNewsWire

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A,...

BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...

7 months ago - GlobeNewsWire

7 Hot Penny Stocks to Watch That Are Trending Right Now

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News a...

7 months ago - PennyStocks

Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.

7 months ago - Zacks Investment Research

Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains

Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted by Cocrystal conduct...

7 months ago - Benzinga

Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Vari...

BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...

7 months ago - GlobeNewsWire

Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

7 months ago - GlobeNewsWire